Welcome to Conformetrix

 

Conformetrix is a drug discovery company at the cutting-edge of ligand-based design.  We develop new drugs by copying the templates provided by other bioactive ligands.    

 

4D-structure of polysaccharide Hyaluronan

 

Our platform technology is a powerful set of analytical tools that can record the dynamic range of motion that molecules explore in solution with extremely high precision.  We call this data a molecules' 4D-structure. By analysing this structure we can identify the bioactive shape of any optimised ligand.  This is a true world first.  It finally realises an entirely new and complementary strategy to high-throughput screening that works for any disease target. 

 

Our unique competitive advantage is in being able to copy Mother Nature’s own "blockbuster blueprints": the peptide hormones and other natural signalling molecules that regulate the human body's functions.  These ligands have been optimised over millions of years of evolution to be highly potent yet highly target-specific - the perfect profile for a therapeutic drug.

 

Learn more ...



 

 

 

 

December 2009

 

Meet Conformetrix at the Genesis meeting in London (10-11 Dec).

 

September 2009

 

Conformetrix appoints Dr Sam Williams (CEO of Modern Biosciences) as a non-exec director.

 

July 2009

 

Conformetrix scientists publish work on the alpha-7 nicotinic receptor in collaboration with scientists at Oxford, Kinki and Kyoto Universities.

 

April 2009


Conformetrix is awarded a prestigous GRAND award for innovative R&D by the NWDA..

 

March 2009

 

Conformetrix launches its new virtual screening service at the EuroCUP computational chemistry workshop in Toledo, Spain.

 

December 2008

 

Conformetrix wins the Bionow Start-up of the Year (2008) Award.